Krystyna Kowalczyk joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss innovation and leadership in oncology clinical trials.
The founder and CEO of OncoBay Clinical, Krystyna shares her efforts to break the mold when it comes to cancer research, and explores OncoBay’s “just in time” enrollment model and why investing up-front in site preparedness is critical to impacting clinical research.
Krystyna Kowalczyk is the CEO and President of OncoBay Clinical. The boutique CRO is not the first company she’s founded. She began her career in drug-device combination work but soon made the move to the CRO side, where she saw plenty of potential for making a significant impact in the research space.
It was Krystyna’s clear-eyed assessment of the industry that drove her to found OncoBay Clinical. Determined to build a fresh, modern CRO worthy of the ever-evolving oncology field, Krystyna and her team embraced an innovative approach to how digital tools and predictive analytics could change the research paradigm.
The willingness to constantly evaluate and adapt is fundamental to their work advancing immuno-oncology research.
- The three tenets of OncoBay’s approach to cutting-edge cancer research
- How to prepare staff for the complexities of a 21st-century oncology trial
- Why we need to evolve from serial to real-time data assessment
- OncoBay’s “just-in-time” enrollment model (and a touching success story)
- Why investing up-front in site preparedness is critical to maximizing impact in research
- How the just-in-time model can help address diversity challenges in enrollment
- Why new technologies and methodologies often create discomfort, and what leaders can do about it
- How you can make 1 + 1 equal 3 when you combine tools effectively
- Why putting together the right team is both more challenging and more critical than putting together the technology
- What Krystyna looks for when assessing potential team members
- Why she’s excited for the next generation of industry employees